Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 15.95M | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 |
Gross Profit | 15.01M | -942.40K | 6.85M | -131.00K | -33.99K | 0.00 |
EBITDA | -214.24M | -221.97M | -166.07M | -207.81M | -379.16M | -10.29M |
Net Income | -230.37M | -235.76M | -151.09M | -216.21M | -10.66M | -10.66M |
Balance Sheet | ||||||
Total Assets | 492.13M | 576.80M | 360.25M | 444.31M | 629.63M | 11.72M |
Cash, Cash Equivalents and Short-Term Investments | 250.72M | 482.18M | 256.55M | 393.64M | 595.08M | 7.23M |
Total Debt | 118.14M | 117.23M | 84.59M | 69.80M | 75.70M | 5.63M |
Total Liabilities | 147.21M | 175.25M | 124.00M | 108.14M | 138.08M | 34.14M |
Stockholders Equity | 344.92M | 401.55M | 236.24M | 336.17M | 491.55M | -22.42M |
Cash Flow | ||||||
Free Cash Flow | -144.05M | -142.09M | -160.51M | -201.68M | -136.33M | -10.63M |
Operating Cash Flow | -143.89M | -142.06M | -160.34M | -200.55M | -136.14M | -10.63M |
Investing Cash Flow | -192.38M | 31.27M | -127.00M | -931.00K | 63.25M | 0.00 |
Financing Cash Flow | 253.64M | 364.75M | 21.12M | 457.00K | 660.07M | 1.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $2.23B | 3.56 | 64.05% | ― | 30.57% | ― | |
60 Neutral | $3.14B | ― | -33.26% | ― | -49.51% | -44.09% | |
56 Neutral | $2.09B | 21.22 | -10.10% | ― | ― | ― | |
54 Neutral | $2.93B | ― | -34.80% | ― | 2816.21% | 73.33% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
41 Neutral | $1.68B | ― | -41.94% | ― | -82.90% | -155.64% | |
33 Underperform | $2.25B | ― | -72.95% | ― | 117.83% | -14.45% |
Centessa Pharmaceuticals announced updates on its OX2R agonist pipeline, including ORX750, ORX142, and ORX489, with significant clinical milestones anticipated in 2025. The company aims to position itself as a leader in the emerging category of OX2R agonist therapeutics, bolstered by a strong balance sheet and an estimated cash runway into mid-2027.